Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.81M | 1.82M | 649.60K | 652.40K | 948.20K |
| Total Other Revenue | 1.48M | 1.49M | 1.76M | 1.77M | 1.81M |
| Total Revenue | 3.29M | 3.31M | 2.41M | 2.42M | 2.76M |
| Cost of Revenue | 9.81M | 9.87M | 13.45M | 13.50M | 11.64M |
| Gross Profit | -6.52M | -6.56M | -11.03M | -11.08M | -8.89M |
| SG&A Expenses | 4.53M | 4.56M | 5.60M | 5.63M | 5.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.35M | 14.43M | 19.05M | 19.13M | 17.19M |
| Operating Income | -11.06M | -11.12M | -16.64M | -16.71M | -14.43M |
| Income Before Tax | -11.41M | -11.48M | -16.20M | -16.27M | -12.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.41M | -11.48M | -16.20M | -16.27M | -12.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.41M | -11.48M | -16.20M | -16.27M | -12.11M |
| EBIT | -11.06M | -11.12M | -16.64M | -16.71M | -14.43M |
| EBITDA | -10.88M | -10.95M | -16.44M | -16.51M | -14.22M |
| EPS Basic | -0.12 | -0.12 | -0.18 | -0.18 | -0.14 |
| Normalized Basic EPS | -0.08 | -0.08 | -0.11 | -0.11 | -0.09 |
| EPS Diluted | -0.12 | -0.12 | -0.18 | -0.18 | -0.14 |
| Normalized Diluted EPS | -0.08 | -0.08 | -0.11 | -0.11 | -0.09 |
| Average Basic Shares Outstanding | 93.83M | 93.83M | 92.25M | 92.25M | 86.94M |
| Average Diluted Shares Outstanding | 93.83M | 93.83M | 92.25M | 92.25M | 86.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |